ProShare Advisors
BDTX icon

ProShare Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

ProShare Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,201
Closed -$24K – 2102
2024
Q4 		$24K Buy
+11,201
New +$32.1K ﹤0.01% 2250
2022
Q1 		– Sell
-10,082
Closed -$53K – 2214
2021
Q4 		$53K Sell
10,082
-573
-5% -$4K ﹤0.01% 2277
2021
Q3 		$90K Sell
10,655
-1,751
-14% -$17.3K ﹤0.01% 1924
2021
Q2 		$151K Buy
12,406
+2,577
+26% +$50.9K ﹤0.01% 2215
2021
Q1 		$238K Buy
9,829
+270
+3% +$7.28K ﹤0.01% 1933
2020
Q4 		$306K Buy
+9,559
New +$314K ﹤0.01% 1597

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ProShare Advisors's BDTX Position: Q1 2025 in Review

ProShare Advisors sold out of Black Diamond Therapeutics (BDTX) in Q1 2025, closing a stake of 11,201 shares — an estimated $24K sold.

ProShare Advisors first reported a position in BDTX in Q4 2020 and held it in 6 quarters. The position peaked at $306K in Q4 2020. 84 funds tracked by Wall St. Rank hold BDTX as of Q1 2025.

  • ProShare Advisors reported no remaining Black Diamond Therapeutics position as of Q1 2025 after selling out during the quarter.
  • ProShare Advisors sold 11,201 Black Diamond Therapeutics shares in Q1 2025, an estimated $24K.
  • ProShare Advisors first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 6 quarters.
  • ProShare Advisors's Black Diamond Therapeutics position peaked at $306K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.